Globus Medical Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Dan Scavilla

Chief Executive Officer (CEO)

US$4.6m

Compensación total

Porcentaje del salario del CEO	10.2%
Permanencia del CEO	2.1yrs
Participación del CEO	n/a
Permanencia media de la dirección	5.1yrs
Promedio de permanencia en la Junta Directiva	5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Dan Scavilla en comparación con los beneficios de Globus Medical?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	US$67m
Dec 31 2023	US$5m	US$464k	US$123m
Sep 30 2023	n/a	n/a	US$158m
Jun 30 2023	n/a	n/a	US$204m
Mar 31 2023	n/a	n/a	US$201m
Dec 31 2022	US$4m	US$437k	US$190m
Sep 30 2022	n/a	n/a	US$155m
Jun 30 2022	n/a	n/a	US$155m
Mar 31 2022	n/a	n/a	US$142m
Dec 31 2021	US$2m	US$396k	US$149m
Sep 30 2021	n/a	n/a	US$187m
Jun 30 2021	n/a	n/a	US$184m
Mar 31 2021	n/a	n/a	US$122m
Dec 31 2020	US$2m	US$384k	US$102m
Sep 30 2020	n/a	n/a	US$95m
Jun 30 2020	n/a	n/a	US$89m
Mar 31 2020	n/a	n/a	US$148m
Dec 31 2019	US$2m	US$366k	US$155m
Sep 30 2019	n/a	n/a	US$146m
Jun 30 2019	n/a	n/a	US$143m
Mar 31 2019	n/a	n/a	US$150m
Dec 31 2018	US$2m	US$355k	US$156m
Sep 30 2018	n/a	n/a	US$144m
Jun 30 2018	n/a	n/a	US$134m
Mar 31 2018	n/a	n/a	US$118m
Dec 31 2017	US$1m	US$345k	US$107m

Compensación vs. Mercado: La compensación total de Dan($USD4.56M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD3.29M).

Compensación vs. Ingresos: La compensación de Dan ha sido consistente con los resultados de la empresa en el último año.

CEO

Dan Scavilla (58 yo)

2.1yrs

Permanencia

US$4,564,374

Compensación

Mr. Daniel T. Scavilla, also known as Dan, serves as President and Chief Executive Officer at Globus Medical, Inc. since April 21, 2022 and serves as its Director since April 2022. He had been Executive Vi...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
David Paul	Co-Founder & Executive Chairman	21.3yrs	US$3.22m	16.48% $ 1.3b
Daniel Scavilla	President	2.1yrs	US$4.56m	sin datos
Keith Pfeil	CFO & COO	4.8yrs	US$2.06m	0% $ 0
Kelly Huller	Senior VP	5.4yrs	US$1.64m	0% $ 0
Brian Kearns	Senior Vice President of Business Development & Investor Relations	no data	sin datos	sin datos

5.1yrs

Permanencia media

56yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de GM0N es experimentado (5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
David Paul	Co-Founder & Executive Chairman	21.3yrs	US$3.22m	16.48% $ 1.3b
Daniel Scavilla	President	2.1yrs	US$4.56m	sin datos
Ann Rhoads	Independent Director	12.8yrs	US$490.69k	0.017% $ 1.4m
John DeFord	Independent Director	less than a year	US$276.27k	0.012% $ 935.5k
Stephen Zarrilli	Independent Director	5yrs	US$470.69k	0% $ 0
James Tobin	Independent Director	8.8yrs	US$478.19k	0% $ 0
Daniel Wolterman	Independent Director	less than a year	US$278.15k	0.018% $ 1.4m
Robert Douglas	Independent Director	4.4yrs	US$470.69k	0.0015% $ 120.1k
David Davidar	Independent Director	21.2yrs	US$468.19k	0.59% $ 47.6m
Leslie Norwalk	Independent Director	less than a year	US$278.77k	0.013% $ 1.0m
Daniel Lemaitre	Independent Director	13.1yrs	US$478.19k	0.0080% $ 649.1k

5.0yrs

Permanencia media

61yo

Promedio de edad

Junta con experiencia: La junta directiva de GM0N se considera experimentada (4.9 años de antigüedad promedio).

Globus Medical Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Globus Medical, Inc., Annual General Meeting, Jun 05, 2024

Globus Medical Promotes Keith Pfeil to Chief Operating Officer

Insufficient new directors

Globus Medical, Inc., Annual General Meeting, Jun 02, 2022

Recent updates

Globus Medical, Inc. Updates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.053 loss per share (vs US$0.49 profit in 1Q 2023)

Globus Medical, Inc., Annual General Meeting, Jun 05, 2024

Globus Medical, Inc. to Report Q1, 2024 Results on May 07, 2024

Globus Medical, Inc. Reaffirms Revenue Guidance for the Full Year 2024

New minor risk - Profit margin trend

Full year 2023 earnings released: EPS: US$1.09 (vs US$1.89 in FY 2022)

Globus Medical Promotes Keith Pfeil to Chief Operating Officer

Globus Medical, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Globus Medical, Inc. Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: US$0.009 (vs US$0.48 in 3Q 2022)

Globus Medical, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Globus Medical, Inc. (NYSE:GMED) completed the acquisition of NuVasive, Inc. (NasdaqGS:NUVA) from BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc., Thrivent Financial for Lutherans and others.

Globus Medical, Inc. Updates Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: EPS: US$0.57 (vs US$0.54 in 2Q 2022)

Globus Medical, Inc. Announces Launch of the Marvel(Tm) Growing Rod System

Globus Medical, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Globus Medical, Inc.(NYSE:GMED) dropped from Russell 1000 Growth-Defensive Index

Globus Medical, Inc. Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings released: EPS: US$0.49 (vs US$0.38 in 1Q 2022)

Full year 2022 earnings released: EPS: US$1.89 (vs US$1.48 in FY 2021)

Investor sentiment deteriorates as stock falls 18%

Globus Medical, Inc. (NYSE:GMED) entered into a definitive agreement to acquire NuVasive, Inc. (NasdaqGS:NUVA) for $3.1 billion.

Globus Medical, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Insufficient new directors

Third quarter 2022 earnings released: EPS: US$0.48 (vs US$0.47 in 3Q 2021)

Globus Medical, Inc. Reaffirms Net Sales Guidance for the Year 2022

Globus Medical, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Globus Medical, Inc. Reaffirms Sales Guidance for the Full Year 2022

Second quarter 2022 earnings released: EPS: US$0.54 (vs US$0.41 in 2Q 2021)

Globus Medical, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Globus Medical, Inc. Announces First Surgeries Using Excelsius3D™

First quarter 2022 earnings released: EPS: US$0.38 (vs US$0.45 in 1Q 2021)

Globus Medical, Inc., Annual General Meeting, Jun 02, 2022

Globus Medical, Inc. to Report Q1, 2022 Results on May 10, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Globus Medical, Inc. Provides Net Sales Guidance for the Full Year 2022

Globus Medical, Inc. to Report Q4, 2021 Results on Feb 17, 2022

Third quarter 2021 earnings released: EPS US$0.47 (vs US$0.45 in 3Q 2020)

Globus Medical, Inc. Announces First ExcelsiusGPS® Cranial Surgery

Globus Medical, Inc. Raises Earnings Guidance for the Full Year 2021

Second quarter 2021 earnings released: EPS US$0.41 (vs US$0.21 loss in 2Q 2020)

Globus Medical Announces Completion of 20,000 Procedures Utilizing ExcelsiusGPS®

First quarter 2021 earnings released: EPS US$0.45 (vs US$0.26 in 1Q 2020)

Globus Medical, Inc. Raises Earnings Guidance for the Full Year 2021

Full year 2020 earnings released: EPS US$1.04 (vs US$1.57 in FY 2019)

Revenue beats expectations

Globus Medical, Inc. to Report Q4, 2020 Results on Feb 17, 2021

Globus Medical, Inc.(NYSE:GMED) dropped from Russell 2000 Defensive Index

Globus Medical, Inc. Wins Group Purchasing Agreement with Premier

Globus Medical, Inc. to Report Q3, 2020 Results on Oct 28, 2020

Northwest Specialty Hospital Partners with Globus Medical, Inc to Implement the First Fully Navigated Spinal Surgery for Minimally Invasive Interbody Spine Fusion Procedures

Globus Medical, Inc. (NYSE:GMED) acquired Synoste Oy for $33.3 million.

Globus Medical, Inc. Withdrew Previously Announce Full Year 2020 Guidance

Globus Medical, Inc. to Report Q2, 2020 Results on Aug 05, 2020

Globus Medical, Inc.(NYSE:GMED) dropped from Russell 2000 Defensive Index

Globus Medical, Inc.(NYSE:GMED) dropped from Russell 2500 Growth Index

Globus Medical, Inc.(NYSE:GMED) dropped from Russell 2000 Index

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad